Customer Demand & Project Design
We begin with in-depth discussions to understand your specific needs, designing a customized experimental plan aligned with your strategic goals.
We DO NOT PROVIDE ANY PRODUCTS OR SERVICES DIRECTLY TO PATIENTS. All of our products are for Research Use Only (RUO), NOT intended for diagnostic, therapeutic, or clinical use.
Antiviral therapy offers significant benefits for monkeypox patients, aiding in treatment and controlling infection spread. With decades of specialized expertise in monkeypox research, Creative Biolabs leverages a team of highly respected strategic and technical advisors, ensuring unparalleled scientific guidance and innovative solutions for your drug discovery needs.
The Monkeypox virus (MPXV) poses an enduring public health threat, which can induce a rare disease, monkeypox. As an Orthopoxvirus, MPXV employs sophisticated immune evasion strategies, particularly against the host's crucial interferon (IFN) signaling pathway. Developing antiviral drugs that target or restore this pathway is of paramount importance. This approach promises to enhance the body's natural defenses, offering a powerful and broadly applicable strategy against current and future orthopoxvirus challenges.
Fig.1 Immunity evasion by MPXV.1
We utilize high-throughput platforms to rapidly screen vast compound libraries. This allows us to efficiently identify potential IFN pathway regulators or antiviral molecules that directly target the MPXV.
We employ specific methods like Luciferase reporter gene assays and Western Blot to detect IFN pathway activation. This includes monitoring key protein phosphorylation and transcription factor activation, such as STAT1/2 phosphorylation, offering detailed insights into drug effects on signaling.
To evaluate drug regulation of the IFN response, we quantitatively detect the expression levels of IFN-stimulated genes (ISGs) in stimulated cells using technologies like qRT-PCR and RNA-seq. We focus on crucial ISGs like MX1, OAS, and PKR.
Conducted within our Biosafety Level 3 (BSL-3) laboratory, we evaluate candidate drugs' inhibitory effects on MPXV replication at the cellular level. We then verify if these effects are mediated through IFN-related mechanisms, assessing viral load determination and cytopathic effect (CPE) inhibition.
We rigorously assess candidate drugs to ensure they do not cause excessive damage to normal cells in vitro. This crucial step supports the development of compounds with a favorable safety profile.
Based on initial screening results, we offer services for lead compound optimization and active molecule synthesis. This aims to enhance the drug's pharmacodynamic and pharmacokinetic properties, advancing its development potential.
Creative Biolabs provides access to established MPXV infection animal models for preclinical validation. These include cost-effective mouse models for initial efficacy and safety, and highly relevant non-human primate models for evaluating drug efficacy and immunogenicity that mimic human infection. Each model is chosen based on research objectives.
Creative Biolabs offers flexible and expert design for experimental protocols and dosing methods. Our team tailors approaches, including oral or various injection routes, to ensure optimal drug exposure and robust experimental outcomes for your project.
Our collaborative process integrates seamlessly with your research goals for efficient drug discovery.
We begin with in-depth discussions to understand your specific needs, designing a customized experimental plan aligned with your strategic goals.
We clarify the cooperation process, ensuring transparency and mutual understanding before officially launching the project.
Our expert scientists precisely execute all operational stages, including in vitro and in vivo screening, compound synthesis, and verification, ensuring rigorous controls and robust methodologies.
Post-execution, we perform comprehensive data analysis using advanced bioinformatics. Findings are compiled into detailed reports, providing clear, actionable insights into drug performance.
We promptly deliver final results and reports, offering continuous follow-up consultation and expert support for subsequent research phases.
Click the button to contact us for service details and a custom quote.
The MPXV actively engages in a sophisticated battle with the host's IFN signaling pathway. MPXV has evolved numerous immunomodulatory proteins, such as the vaccinia virus (VACV) IFN-binding molecule (IBM) and COP-B19 orthologs, which directly interfere with IFN production, inhibit critical signaling components like the JAK-STAT pathway, or neutralize the antiviral effects of IFN-stimulated genes (ISGs). Our drug discovery services are specifically designed to target these viral evasion mechanisms, aiming to restore or significantly enhance the host's natural IFN-mediated antiviral immunity, thereby effectively combating MPXV infection.
Professional Biosafety Laboratory
Our dedicated BSL-3 laboratory ensures the utmost safety and regulatory compliance for all MPXV experiments, providing a secure environment for sensitive research.
Rich Experience in Virology and Immunology
With over 20 years of experience, our team of world-renowned virologists and immunologists brings unparalleled expertise, offering deep scientific insights and strategic guidance throughout your project.
Comprehensive In Vitro/In Vivo Integrated Platform
We offer a seamless, one-stop solution encompassing both in vitro and in vivo studies, streamlining your research and development process from target validation to preclinical candidate selection.
Customized Service Capabilities
Our approach is highly flexible, allowing for tailored experimental designs that precisely meet your unique research objectives and specific needs, ensuring optimal project outcomes.
High-Throughput Screening Capabilities
Leveraging advanced high-throughput screening (HTS) platforms, we efficiently screen vast compound libraries, significantly accelerating the identification of promising drug candidates for large-scale projects.
Absolutely. Our services include robust target identification and validation capabilities. We employ advanced bioinformatics, proteomics, and screening techniques to pinpoint key viral immunomodulators or host factors that interact with the IFN pathway, providing a solid foundation for novel drug discovery.
In our in vivo studies, we utilize a comprehensive set of evaluation indicators to assess drug effectiveness. These include quantifying viral load in various tissues and blood, conducting detailed pathological analyses of organ damage, and profiling host immune responses, such as cytokine levels and immune cell infiltration. Clinical scoring and weight changes are also meticulously monitored.
Yes, customization is a cornerstone of our service philosophy. We understand that each drug discovery project is unique. Our scientific team works closely with you to design bespoke experimental protocols, including specific assay parameters, dosing regimens, and evaluation endpoints, ensuring the research directly addresses your precise requirements.
Confidentiality is paramount in our operations. We adhere to strict confidentiality agreements and implement robust data security protocols to protect all proprietary information, including your compounds and research data. Our internal systems and procedures are designed to ensure the highest level of privacy and intellectual property protection throughout the collaboration.
Given the shared genetic and antigenic similarities among Orthopoxviruses, our expertise and platforms are broadly applicable. While our primary focus here is Monkeypox, we can discuss and potentially adapt our services to address drug discovery efforts against other related orthopoxviruses, leveraging our extensive experience in the field.
Creative Biolabs is an innovative and experienced anti-Monkeypox drug discovery solutions provider. An in-depth understanding of drug targets is essential for drug development. If you are interested in our drug discovery services or research products, please feel free to contact us for more.
Reference
We DO NOT PROVIDE ANY PRODUCTS OR SERVICES DIRECTLY TO PATIENTS. All of our products are for Research Use Only (RUO), NOT intended for diagnostic, therapeutic, or clinical use.